What dose of alpha lipoic acid works for neuropathy?

600 mg daily. SYDNEY 2 tested up to 1,800 mg and found no extra symptom benefit above 600 mg, only more nausea.

Should I take it with food?

No. Food markedly reduces absorption. Take it at least 30 minutes before eating.

Does it repair nerve damage?

Not proven. It reliably improves symptoms, but the four-year NATHAN 1 trial did not meet its primary endpoint for nerve conduction and impairment combined.

How long before I notice anything?

Trials saw symptom improvement within three to five weeks. Six weeks is a fair test.

Is R-lipoic acid better?

It is better absorbed, but every major trial used the racemic form, so the 600 mg evidence applies to that.

Can it cause low blood sugar?

It can, by improving insulin sensitivity. If you use insulin or a sulfonylurea, monitor closely when you start.

Does it help non-diabetic neuropathy?

The trial evidence is in diabetic polyneuropathy. Other causes such as B12 deficiency or chemotherapy have their own treatments and should be investigated.

Condition

Moderate Evidence

Effectiveness 3/5

Alpha Lipoic Acid (ALA) for Peripheral Neuropathy

Alpha-lipoic acid at 600mg daily reduces burning and numbness in diabetic neuropathy across several randomised trials — the best-supported supplement here.

Overview

Alpha lipoic acid has the best evidence of any supplement for the burning, stabbing and prickling of diabetic peripheral neuropathy. The SYDNEY 2 trial showed 600 mg daily improved neuropathic symptoms over five weeks, and a 2012 meta-analysis of randomised trials confirmed a consistent symptomatic benefit across the literature. It is approved as a prescription treatment for diabetic neuropathy in Germany, which is unusual company for a supplement. The distinction that matters is symptoms versus nerve damage. The four-year NATHAN 1 trial did not meet its primary composite endpoint of combined neuropathy impairment and nerve conduction change, though it did show improvement on neuropathic deficits. So the fair claim is that alpha lipoic acid reliably takes the edge off symptoms; whether it slows the underlying nerve degeneration remains unproven. Glycaemic control is still the intervention that changes the trajectory.

Verdict

Likely effective

Randomised trials and a meta-analysis show 600 mg daily alpha lipoic acid improves neuropathic pain, burning and paraesthesia in diabetic polyneuropathy. Long-term trial data did not confirm a change in nerve conduction.

How It Works

Diabetic neuropathy is driven substantially by oxidative and nitrosative stress. Chronic hyperglycaemia pushes glucose into the polyol pathway, generates advanced glycation end products and increases mitochondrial superoxide production, all of which damage the microvasculature supplying peripheral nerves and the axons themselves. Alpha lipoic acid is unusual among antioxidants in being both water and fat soluble, so it acts in the cytosol and in membranes, and it regenerates glutathione, vitamin C and vitamin E rather than being consumed once. Beyond scavenging, it improves endoneurial blood flow and nerve conduction velocity in experimental models, inhibits the polyol pathway, and enhances insulin-stimulated glucose uptake. The rapid symptomatic effect — weeks rather than months — suggests the early benefit comes from improved nerve perfusion and reduced oxidative irritation of nociceptive fibres rather than from structural regeneration.

Pathways involved

Reactive oxygen species scavenging

Glutathione and antioxidant regeneration

Endoneurial blood flow

Polyol pathway inhibition

Insulin-stimulated glucose uptake

Advanced glycation end product formation

Dosing & Protocol

600 mg per day is the dose the evidence supports. SYDNEY 2 tested 600, 1,200 and 1,800 mg and found no additional symptomatic benefit above 600 mg, only more nausea and vomiting at higher doses. NATHAN 1 used 600 mg daily over four years. There is no case for exceeding it. Take it on an empty stomach — at least 30 minutes before food — because food substantially reduces absorption. Bioavailability of the standard racemic form is modest and variable; the R-isomer is better absorbed, but the trials used the racemic mixture, so that is what the dose refers to. Symptomatic improvement in trials appeared within three to five weeks, so a six-week course is a reasonable test.

Scenario	Dose	Form	Timing
Trial standard (SYDNEY 2, NATHAN 1)	600 mg/day	Racemic alpha lipoic acid, oral	30-60 minutes before food
Higher doses tested	1,200-1,800 mg/day	Oral	No added benefit; more nausea and vomiting
Split option	300 mg twice daily	Oral	Both doses away from food
R-isomer alternative	Typically 200-300 mg/day	R-lipoic acid	Better absorbed but not the studied form
Assessment period	3-6 weeks	-	Symptom change appeared by week 5 in trials
Long-term use	600 mg/day	Oral	Used safely over 4 years in NATHAN 1

1
Confirm the cause of the neuropathy· Before starting
Diabetic polyneuropathy is where the evidence sits. B12 deficiency, alcohol, thyroid disease, chemotherapy and compressive causes need their own treatment.
2
Fix glycaemic control in parallel· Ongoing
Glucose control is the only intervention shown to alter the course of diabetic neuropathy. Alpha lipoic acid is symptomatic relief on top of it.
3
Start 600 mg daily before food· Weeks 1-6
At least 30 minutes before breakfast, or split as 300 mg twice daily away from meals.
4
Monitor blood glucose more closely at first· Weeks 1-2
Alpha lipoic acid improves insulin sensitivity and can lower glucose, which matters if you take insulin or a sulfonylurea.
5
Judge at 6 weeks· Week 6
Rate burning, stabbing, numbness and prickling. Trials saw change by week five; no improvement by week six means it is unlikely to work for you.

Evidence

SYDNEY 2, published in Diabetes Care in 2006, randomised patients with diabetic polyneuropathy to oral alpha lipoic acid at three doses or placebo for five weeks. All active doses improved the Total Symptom Score significantly more than placebo, with 600 mg giving the best benefit-to-tolerability ratio — the key practical finding that fixed the standard dose. The 2012 meta-analysis in the International Journal of Endocrinology pooled randomised trials and confirmed significant improvement in neuropathic symptoms, noting that intravenous administration produced larger effects than oral in the older literature. NATHAN 1, a four-year randomised trial also in Diabetes Care, is the most demanding test: it did not meet its primary composite endpoint combining nerve conduction and impairment measures, but it did show improvement in neuropathic impairment scores and confirmed long-term safety at 600 mg daily. Together these establish symptomatic benefit clearly and disease modification not at all.

Best available evidence: Two randomised controlled trials including a 4-year trial, plus a meta-analysis
Typical effect: Meaningful reduction in burning, stabbing, paraesthesia and numbness scores
Studied dose: 600 mg/day oral racemic alpha lipoic acid
Time to effect: 3-5 weeks
What is not established: Improvement in nerve conduction or slowing of nerve damage
Certainty of evidence: Moderate to strong for symptoms; insufficient for disease modification

The SYDNEY 2 randomised dose-ranging trial of oral alpha lipoic acid, the four-year NATHAN 1 trial, and a meta-analysis of randomised controlled trials in symptomatic diabetic peripheral neuropathy.

Efficacy and safety of antioxidant treatment with alpha-lipoic acid over 4 years in diabetic polyneuropathy: the NATHAN 1 trial

Score: 9/10

2011

rct

n=460

Ziegler D, Low PA, Litchy WJ +3 more

Efficacy and safety of antioxidant treatment with alpha-lipoic acid over 4 years in diabetic polyneuropathy.

View source

Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial

Score: 8/10

2006

rct

n=181

Ziegler D, Ametov A, Barinov A +3 more

Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial.

View source

Alpha lipoic acid for symptomatic peripheral neuropathy in patients with diabetes: a meta-analysis of randomized controlled trials

Score: 8/10

2012

meta_analysis

n=653

Mijnhout GS, Kollen BJ, Alkhalaf A +2 more

Alpha lipoic acid for symptomatic peripheral neuropathy in patients with diabetes: a meta-analysis of randomized controlled trials.

View source

Safety

Alpha lipoic acid is well tolerated at 600 mg daily, and NATHAN 1 documented safety over four years of continuous use. The dose-limiting adverse effects are gastrointestinal — nausea, vomiting and abdominal discomfort — and they rise clearly at 1,200 mg and above, which is one of the reasons not to exceed 600 mg. Skin rash and, rarely, an odd smell to the urine are also reported. The clinically important effect is on glucose. Alpha lipoic acid improves insulin sensitivity, so people taking insulin or sulfonylureas can experience hypoglycaemia and may need dose adjustment. It also chelates metals, which is relevant to anyone with iron or copper supplementation. Thiamine deficiency, common in heavy alcohol use, should be corrected first because alpha lipoic acid increases thiamine demand. Rare cases of insulin autoimmune syndrome have been reported, mainly in East Asian populations with a specific HLA type. Safety in pregnancy has not been established.

Watch your glucose in the first fortnight

Alpha lipoic acid improves insulin sensitivity. If you take insulin or a sulfonylurea, test more often for the first two weeks — dose reductions are sometimes needed to avoid hypoglycaemia.

Interactions & Conflicts

Interacts with	Severity	Mechanism	Action
Insulin and sulfonylureas	high	Additive glucose lowering through improved insulin sensitivity	Monitor blood glucose; dose adjustment may be needed
Levothyroxine and thyroid hormone	moderate	May interfere with thyroid hormone conversion and absorption	Separate doses and monitor thyroid function
Iron, copper and magnesium supplements	moderate	Alpha lipoic acid chelates metal ions	Separate by at least 2 hours
Thiamine deficiency and heavy alcohol use	moderate	Increases thiamine demand and may worsen deficiency	Correct thiamine status first
Chemotherapy	moderate	Theoretical antioxidant interference with oxidative cytotoxic agents	Only under oncology guidance
Pregnancy and breastfeeding	moderate	No adequate safety data	Avoid
Vitamin B12 deficiency neuropathy	low	Symptom relief may mask an untreated deficiency	Check B12 before attributing neuropathy to diabetes

References

Frequently Asked Questions

Medical Disclaimer

The information provided on this website is for educational and informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or before starting any supplement regimen.

Individual results may vary. The statements on this website have not been evaluated by the Food and Drug Administration. Products and information are not intended to diagnose, treat, cure, or prevent any disease.